| Literature DB >> 30309234 |
Jin Soo Lee1, Seong-Joon Lee1, Joon Sang Yoo2, Jeong-Ho Hong2, Chang-Hyun Kim3, Yong-Won Kim4,5, Dong-Hun Kang5,6, Yong-Sun Kim5, Ji Man Hong1, Jin Wook Choi7, Bruce Ovbiagele8, Andrew M Demchuk9, Sung-Il Sohn2, Yang-Ha Hwang4.
Abstract
BACKGROUND ANDEntities:
Keywords: Atherosclerosis; Cerebral infarction; Embolism; Reperfusion; Thrombectomy; Treatment outcome
Year: 2018 PMID: 30309234 PMCID: PMC6186924 DOI: 10.5853/jos.2018.01627
Source DB: PubMed Journal: J Stroke ISSN: 2287-6391 Impact factor: 6.967
Figure 1.Study flow chart. ASIAN KR, Acute Stroke due to Intracranial Atherosclerotic occlusion and Neurointervention-Korean Retrospective; ICA, internal carotid artery; ICAS, intracranial atherosclerotic stenosis; MCA, middle cerebral artery; ACA, anterior cerebral artery.
Comparison of baseline characteristics and risk factors among groups
| Characteristic | Embolic group (n=421) | ICAS group (n=99) | |
|---|---|---|---|
| Age (yr) | 68.2±12.4 | 64.8±13.7 | 0.017 |
| Male sex | 208 (49.4) | 60 (60.6) | 0.045 |
| Premorbid mRS score | 0 (0–0) | 0 (0–0) | 0.971 |
| Initial NIHSS score | 17 (13–21) | 15 (11–19) | 0.045 |
| ASPECTS on noncontrast CT | 7 (4–9) | 8 (5–9) | 0.227 |
| Location of occlusive lesions on baseline angiography | <0.001 | ||
| ICA T | 170 (40.4) | 21 (21.2) | |
| MCA M1 | 205 (48.7) | 75 (75.8) | |
| MCA M2 | 46 (10.9) | 3 (3.0) | |
| Hypertension | 257 (61.0) | 59 (59.6) | 0.790 |
| Diabetes mellitus | 96 (22.8) | 27 (27.3) | 0.346 |
| Coronary artery occlusive disease | 53 (12.6) | 7 (7.1) | 0.122 |
| Current smoking | 84 (20.0) | 31 (31.3) | 0.014 |
| Atrial fibrillation | 267 (63.4) | 24 (24.2) | <0.001 |
| Prior antiplatelet | 131 (31.1) | 16 (16.2) | 0.003 |
| Prior anticoagulant | 71 (16.9) | 7 (7.1) | 0.014 |
| Laboratory data | |||
| Blood glucose on admission (mg/dL) | 137.6±52.0 | 143.4±55.1 | 0.322 |
| HbA1c (%) | 6.2±1.1 | 6.2±1.2 | 0.711 |
| Total cholesterol (mg/dL) | 163.0±52.2 | 180.2±42.5 | 0.002 |
| Triglyceride (mg/dL) | 101.3±55.0 | 130.7±141.7 | 0.045 |
| HDL-C (mg/dL) | 47.2±21.6 | 44.7±10.8 | 0.277 |
| LDL-C (mg/dL) | 96.6±34.4 | 114.5±37.8 | <0.001 |
| ESR (mm/hr) | 14.1±14.5 | 15.0±14.7 | 0.563 |
| CRP (mg/dL) | 0.68±1.70 | 1.12±3.87 | 0.269 |
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
ICAS, intracranial atherosclerotic stenosis; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Scores; CT, computed tomography; ICA, internal carotid artery; MCA, middle cerebral artery; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
Comparison of treatments and outcomes among groups
| Variable | Embolic group | ICAS group | |
|---|---|---|---|
| Onset-to-puncture time (min) | 235 (165–374) | 320 (245–560) | 0.002 |
| Procedure time (min) | 55 (40–83) | 68 (49–97) | 0.001 |
| Intravenous tPA | 235 (55.8) | 46 (46.5) | 0.093 |
| Balloon guide catheter usage | 311 (73.9) | 67 (67.7) | 0.213 |
| Stent retriever usage | 248 (58.9) | 79 (79.8) | <0.001 |
| Direct aspiration usage | 281 (66.7) | 57 (57.6) | 0.085 |
| Intracranial stenting | 9 (2.1) | 13 (13.1) | <0.001 |
| Intracranial ballooning without stenting | 2 (0.5) | 7 (7.1) | <0.001 |
| Number of techniques | 1 (1–2) | 2 (2–3) | <0.001 |
| Final reperfusion grade (mTICI) | 0.018 | ||
| Grade 0 | 7 (1.7) | 6 (6.1) | |
| Grade 1 | 8 (1.9) | 5 (5.1) | |
| Grade 2a | 71 (16.9) | 12 (12.1) | |
| Grade 2b | 209 (49.6) | 42 (42.4) | |
| Grade 3 | 126 (29.9) | 34 (34.3) | |
| Successful reperfusion (mTICI 2b–3) | 335 (79.6) | 76 (76.8) | 0.537 |
| Final recanalization grade (AOL) | <0.001 | ||
| Grade 0 | 6 (1.4) | 7 (7.1) | |
| Grade 1 | 9 (2.1) | 23 (23.2) | |
| Grade 2 | 31 (7.4) | 54 (54.5) | |
| Grade 3 | 375 (89.1) | 15 (15.2) | |
| Intracerebral hemorrhage | 0.288 | ||
| No hemorrhage | 272 (64.6) | 74 (74.7) | |
| HT type 1 | 33 (7.8) | 6 (6.1) | |
| HT type 2 | 48 (11.4) | 10 (10.1) | |
| PH type 1 | 34 (8.1) | 3 (3.0) | |
| PH type 2 | 34 (8.1) | 6 (6.1) | |
| Serious hemorrhagic complications | 45 (10.7) | 7 (7.1) | 0.280 |
| Reocclusion on repeat angiography | 9 (2.5) | 14 (15.7) | <0.001 |
| 3-Month mRS score | 2 (1–4) | 3 (1–4) | 0.629 |
| Good outcomes at 3 months | 229 (54.5) | 45 (45.5) | 0.104 |
Values are presented as median (interquartile range) or number (%).
ICAS, intracranial atherosclerotic stenosis; tPA, tissue plasminogen activator; mTICI, modified treatment in cerebral ischemia; AOL, arterial occlusive lesion; HT, hemorrhagic transformation; PH, parenchymal hematoma; mRS, modified Rankin Scale.
Figure 2.Modified Rankin Scale (mRS) scores at 3 months. Without adjustments, the distribution of mRS scores and the frequency of good outcomes did not differ between the Embolic and intracranial atherosclerotic stenosis (ICAS) groups.
Results of logistic regression model for evaluating the association between occlusion etiology and good outcome
| Variable | Odds ratio (95% CI) | |
|---|---|---|
| Age (yr) | 0.945 (0.925–0.965) | <0.001 |
| Male sex | 0.989 (0.613–1.596) | 0.964 |
| Premorbid mRS score | 0.578 (0.412–0.810) | 0.001 |
| Initial NIHSS score | 0.897 (0.853–0.942) | <0.001 |
| Baseline intracranial occlusion | 0.398 | |
| ICA T | Reference | |
| MCA M1 | 1.264 (0.757–2.111) | 0.371 |
| MCA M2 | 1.732 (0.747–4.018) | 0.201 |
| ASPECTS | 1.313 (1.200–1.436) | <0.001 |
| Intravenous tPA use | 0.963 (0.566–1.636) | 0.889 |
| Onset to puncture (min) | 0.999 (0.997–1.000) | 0.021 |
| Procedure time (min) | 0.981 (0.974–0.988) | <0.001 |
| Successful reperfusion | 2.451 (1.359–4.418) | 0.003 |
| PH2 or SAH 3–4 | 0.242 (0.094–0.619) | 0.003 |
| Underlying etiology (ICAS vs. embolic occlusion) | 0.495 (0.269–0.913) | 0.024 |
CI, confidence interval; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; ICA, internal carotid artery; MCA, middle cerebral artery; ASPECTS, Alberta Stroke Program Early CT Scores; tPA, tissue plasminogen activator; PH, parenchymal hematoma; SAH, subarachnoid hemorrhage; ICAS, intracranial atherosclerotic stenosis.
Figure 3.Relationship between good outcomes and well-known predictors in endovascular treatment for acute ischemic stroke and comparison between embolic and intracranial atherosclerotic stenosis (ICAS)-related occlusion. (A) The probability of good 3-month outcomes tended to decline in the Embolic group but stayed stable in the ICAS group as onset-to-puncture time increased up to 24 hours. (B-D) The probability of good outcomes appeared to be somewhat less in ICAS-related occlusion than in embolic occlusion; however, this was not statistically significant. NIHSS, National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Scores.